GlassScriptPhysician profile
Renuka Umashanker
NPI 1437130309
$197,046.23
in general payments reported to CMS, 2019-2025
31 companies · $64K in 2025
The $64K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $8,832 · 2021: $17K · 2022: $28K · 2023: $25K · 2024: $28K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Food and Beverage: $9,364 · Travel and Lodging: $7,623 · Honoraria: $3,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,007.50 |
| Food and Beverage | $9,363.71 |
| Travel and Lodging | $7,623.22 |
| Honoraria | $3,877.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $79,635.38 | 2019-2025 | Epclusa |
| Abbvie INC. | $76,518.77 | 2019-2025 | Linzess, Creon, Viberzi |
| Madrigal Pharmaceuticals | $36,053.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,649.18 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $486.07 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $393.29 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $343.39 | 2019-2024 | Linzess |
| Ardelyx, INC. | $325.70 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $283.55 | 2019-2025 | Ocaliva |
| Celgene Corporation | $194.22 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $159.80 | 2019-2025 | Wegovy |
| Pfizer INC. | $153.64 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $110.25 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $96.97 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $74.68 | 2019-2024 | Rebyota |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $65.09 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Allergan, INC. | $62.41 | 2019 | |
| Phathom Pharmaceuticals, INC. | $60.79 | 2023-2025 | Voquezna |
| Braintree Laboratories, INC. | $51.43 | 2022-2023 | Sutab |
| Mirum Pharmaceuticals, INC. | $47.85 | 2025 | Cholbam, Livmarli, Chenodal |
| Shionogi INC | $45.49 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $44.94 | 2024-2025 | Givlaari |
| Lilly USA, LLC | $41.48 | 2024-2025 | Omvoh |
| Echosens North America, INC. | $25.00 | 2019 | |
| Aimmune Therapeutics, INC. | $21.56 | 2024 | |
| Genzyme Corporation | $21.01 | 2023 | |
| Exact Sciences Corporation | $17.64 | 2023 | Cologuard Collection Kit |
| Pentax of America, INC. | $17.60 | 2022 | |
| Merck Sharp & Dohme LLC | $16.10 | 2024 | Dificid |
| Endo Pharmaceuticals INC. | $16.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.80 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renuka Umashanker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.